Silver Spring, MD – January 12, 2026 — Pinco Biotherapeutics, a preclinical company developing a non-viral DNA plasmid therapy targeting Nav1.7 for neuropathic pain, today announced the appointment of Mason Diamond, DDS, and Swami Nathan, MBA, to its Scientific and Business Advisory Board.

The additions strengthen Pinco’s regulatory execution, development strategy, and long-term commercialization planning as the company advances toward in-vivo validation and IND-enabling studies.

Mason W. Diamond, DDS

Dr. Diamond brings more than 30 years of regulatory and product development leadership across biologics, medical devices, and combination products. He has held senior roles at Bayer, Ferring Pharmaceuticals, Integra LifeSciences, and TyRx Pharma (acquired by Medtronic), and has extensive experience interacting with FDA divisions including CBER, CDER, and CDRH.

He has led IND strategy, CMC development planning, orphan designation submissions, and combination product regulatory pathways, and previously served as an Industry Representative on an FDA Advisory Committee.

At Pinco, Dr. Diamond will guide regulatory classification strategy, IND-enabling planning, FDA engagement, and long-term positioning for clinical development and partnering.

Swami Nathan, MBA

Mr. Nathan is a seasoned CNS and specialty pharma commercial leader with executive experience at Eli Lilly, ATAI Life Sciences, Trevena, Promius Pharma, and Immunovant. He has led new product planning, portfolio prioritization, launch strategy, valuation modeling, and market access planning across neurology and pain programs.

He architected the U.S. launch strategy for Cymbalta at Eli Lilly and has extensive experience shaping Target Product Profiles, competitive positioning, and commercialization pathways for emerging therapies.

At Pinco, Mr. Nathan will support indication strategy, value-inflection planning, pricing and access considerations, and long-term commercialization strategy.

“Advanced therapies require disciplined regulatory execution and clear commercial strategy from day one,” said Scott Alpizar, PhD, CEO of Pinco Biotherapeutics. “Mason and Swami bring complementary expertise that strengthens our ability to translate strong science into a clinically and commercially viable therapy.”

The advisory expansion reflects Pinco’s continued effort to deepen its drug development, capital strategy, and partnership capabilities.

About Pinco Biotherapeutics

Pinco Biotherapeutics is a preclinical therapeutics company developing non-viral DNA plasmid–based drugs for chronic neuropathic pain. By directly targeting validated molecular drivers of pain, Pinco’s plasmid is designed to deliver durable, non-addictive relief while avoiding the systemic side effects of small molecules and the immunogenicity risks of viral gene therapies.